Journal of Peptide Science
J. Pept. Sci. 2006; 12: 569–574
Published online 28 July 2006 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/psc.779
Review
Cyclopeptides of Linum usitatissimum
BOLESłAW PICUR,a MAREK CEBRAT,a JANUSZ ZABROCKIb and IGNACY Z. SIEMIONa *
a
b
Faculty of Chemistry, University of Wroclaw, 14 F. Joliot-Curie, 50-383 Wroclaw, Poland
Institute of Organic Chemistry, Technical University of Lodz, Stefanowskiego 4/10, 90-924 Lodz, Poland
Received 15 May 2006; Revised 8 June 2006; Accepted 14 June 2006
Abstract: Cyclolinopeptide A (CLA), a cyclic nonapeptide from linseed, possesses strong immunosuppressive and antimalarial
activity along with the ability to inhibit cholate uptake into hepatocytes. The structure of the peptide was studied extensively
in solution as well as in the solid state. It is postulated that both the Pro–Pro cis-amide bond and an ‘edge-to-face’ interaction
between the aromatic rings of two adjacent Phe residues are important for biological activity. Structure–activity relationship
studies of many linear and cyclic analogues of CLA suggest that the Pro-Xxx-Phe sequence and the flexibility of the peptide are
important for the immunosuppressive activity. Copyright 2006 European Peptide Society and John Wiley & Sons, Ltd.
Keywords: edge-to-face; cyclolinopeptide; cyclosporin; immunomodulation; immunosuppression
DISCOVERY
In 1959, cyclolinopeptide A (CLA) was isolated by Kaufmann and Tobschirbel from the sediments deposited
from crude linseed oil [1]. Ten years later, Prox and
Weygand determined the primary structure of CLA as
a cyclic hydrophobic nonapeptide with the following
sequence [2]:
Pro1-Pro2-Phe3-Phe4-Leu5-Ile6-Ile7-Leu8-Val9
Another similar cyclic nonapeptide named CLB was
isolated in Weygand’s laboratory. It differs from CLA by
the presence of a Met residue and has the following
sequence: cyclo (-Ile-Pro-Pro-Phe-Phe-Val-Ile-Met-Leu-)
[3]. The syntheses of both of these peptides were
performed by Obermeier. The linear precursors of
the peptides with a C-terminal Leu6 residue were
cyclized by the azide activation method [4]. CLB was
rediscovered by Morita et al. at a later time [5]. The
same research group described other cyclic peptides
from Linum [6,7]:
CLC cyclo (-Pro-Pro-Phe-Phe-Val-Ile-Mso-Leu-Ile-)
CLD cyclo (-Pro-Phe-Phe-Trp-Ile-Mso-Leu-Leu-)
CLE cyclo (-Pro-Leu-Phe-Ile-Mso-Leu-Val-Phe-)
CLF cyclo (-Pro-Phe-Phe-Trp-Val-Mso-Leu-Mso-)
CLG cyclo (-Pro-Phe-Phe-Trp-Ile-Mso-Leu-Mso-)
CLH cyclo (-Pro-Phe-Phe-Trp-Ile-Mso-Leu-Met-)
CLI cyclo (-Pro-Phe-Phe-Trp-Val-Met-Leu-Mso-)
At the same time Picur et al. isolated from
Linum album a cyclic peptide CLX, containing nonproteinaceous amino acid N -methyl-4-aminoproline [8].
To evaluate the configuration of the residue X, the
circular dichroism (CD) spectra of natural CLX was
compared with the spectra of the cyclic peptides containing all four stereoisomers of the amino acid. It
followed from the investigations that the X residue in
the natural peptide corresponds to (2S, 4R) N -methyl4-aminoproline (see Figure 1) [9].
STRUCTURE
The conformation of CLA in solution was studied
by CD and NMR spectroscopy, and conformational
energy calculations by Naider et al., Brewster et al.,
and Tonelli, respectively [10–12]. The conformational
preferences predicted in this early work were not
confirmed by later investigations. Naider et al. pointed
at the structural similarity of CLA and antamanide,
a cyclic decapeptide present in Amanita phalloides
tissue but concluded that CLA is much more flexible
in solution than antamanide. Later Siemion et al.
found evidence for the existence of a cis-amide bond
between the two Pro residues in the CLA molecule
[13]. This proposition was supported by X-ray studies
H2N
N
Mso – methionine sulfoxide
* Correspondence to: I. Z. Siemion, Faculty of Chemistry, University of
Wroclaw, 14 Joliot-Curie Str., 50-383 Wroclaw, Poland;
e-mail: siemion@wchuwr.chem.uni.wroc.pl
Copyright 2006 European Peptide Society and John Wiley & Sons, Ltd.
COOH
CH3
Figure 1 The structure of the ‘X’ residue of cyclolinopeptide
X (CLX) [9].
570
PICUR ET AL.
by Di Blasio et al. The authors concluded that ‘the
solid state and solution conformations of CLA are
essentially identical, even if this cyclic system tends
to give rise to a complex mixture of quasi-isoenergetic
conformations, favoured by the flexibility of the ring
enhanced by the isomerism of the Pro–Pro bond
and by the polar solvents [14]. The details of the
crystal structure of CLA are summarized in the recent
article of Benedetti and Pedone [15]. The structure
of CLA in several solvents was studied by NMR
methods by Tancredi et al. [16]. At room temperature
1H-NMR spectra show very broad lines, indicating
the presence of chemical exchange among several
conformers. However, studies in CDCl3 solution at low
temperatures allowed freezing a single conformational
state consistent with the main features of the solidstate structure. The X-ray study of CLA was also
performed by Neela et al. [17] and its conformation
in d6 -DMSO solution via NMR by Raghothama et al.
[18]. A structure very similar to the crystal-state
structures of CLA was also obtained in a case of its
[Aib5,6 , D-Ala8 ]CLA analogue. However, the presence of
two α-amino-isobutyric acid (Aib) residues results in
a very significant enhancement of molecular rigidity
of the compound, even in solution [19]. The X-ray
structure of [Tyr4 ]CLA could also be superimposed
upon that of CLA [20]. A different structure was
found for CLX, where (2S, 4R) N -methyl-4-aminoproline
residue closes a ring formed by the – Pro-Pro-PhePhe-Ile-Leu-Leu- sequence. The X residue plays the
role of a dipeptide moiety with a non-planar cispeptidomimetic bond. All other amide bonds are in the
trans configuration [9]. Distance-geometry calculations
and molecular dynamics simulations were also applied
in the investigation of the conformation of CLA and the
results for the most stable conformations resembled
those in the crystal state [21]. Molecular dynamics
simulations in vacuo and in solution performed by
Saviano et al. showed that CLA exists in water in several
conformations favoured by the intrinsic flexibility of the
molecule caused by the cis-trans isomerism of the two
Xxx-Pro amide bonds. The results of the simulations for
a periodic crystal were in agreement with the X-ray data
and NMR data in CDCl3 solution at low temperature
[22].
The introduction of the Cαα - dialkylated glycine
residue into the peptide sequence (achieved by the
synthesis of cyclo (-Pro-Pro-Phe-Phe-Ac6 c-Ile-D-AlaVal-), where Ac6 c is 1-aminocyclohexane-1-carboxylic
acid) resulted in decreased flexibility of the peptide in
solution [23]. In the crystal state, the peptide possesses
a ‘banana-twisted conformation with a cis-amide bond
between the two Pro residues’ [24].
An interesting feature of the CLA conformation is
the reciprocal orientation of the aromatic rings of
the two Phe residues. The rings are perpendicular
to each other, forming an edge-to-face interaction
Copyright 2006 European Peptide Society and John Wiley & Sons, Ltd.
[25]. The experiments with tyrosine analogues of CLA
unequivocally showed that the residue in the position 4
plays a role of the ‘edge’ and the one in position 3 a role
of the ‘face’ in this interaction. It is also of interest that
in the CD spectra the residue 3 is optically active and
that in position 4 inactive, probably due to the different
side chain conformation of both aromatic residues. This
effect was not observed in the case of linear precursors
of CLA [26].
As we have already noted, CLA can be considered
as an analogue of a cyclic decapeptide, antamanide,
which is known for its ability to form complexes with
metal ions of IA and IIA groups [27]. In the case of CLA,
this tendency for metal ions complexation is strongly
reduced [28]. However, the conductivity measurements
showed that CLA forms a 1 : 1 complex with potassium
cation in methanol solution [29]. NMR and CD conformational studies performed by Tancredi et al. show
that complexes of CLA with Ba+2 ions are stronger than
those with K+ , Na+ , Mg+2 , and Ca+2 . CD data indicate
that two types of such complexes are present in acetonitrile solution depending on the concentration: 1 : 2
sandwiches and 1 : 1 equimolar complexes. NMR data
were consistent with an equimolar form [30]. Addition of
bivalent metal ions to the CLA solution induces drastic
structural changes. In the equimolar Ba+2 /CLA complex the peptide backbone contains all-trans peptide
bonds and the global shape of the complexed peptide can be described as a bowl with a concave (polar)
side hosting Ba+2 and the opposite convex side predominantly apolar. Zanotti et al. studied a structural
analogue of CLA called CYS7 and found that the peptide
preferentially binds calcium ions forming an equimolar
complex similar in its overall shape to that of Ba+2 /CLA
complex with a clear separation of two hydrophobic/hydrophilic surfaces [31]. The conformational features of both free and Ca+2 -complexed CLA analogues:
cyclo-[Pro-Phe-Phe-Ala-Xaa]2 have been recently determined by NMR spectroscopy and extensive distancegeometry calculations. The Ca+2 -complexed peptides
presented two cis-peptide bonds and were generally
similar to those observed for the metal-complexed forms
of antamanide and related analogues [32].
BIOLOGICAL ACTIVITY
The original role of CLA in linseed remains unknown.
The first biological activity found for this peptide was its
ability to inhibit cholate uptake into hepatocytes. In this
regard, CLA resembles antamanide and somatostatin.
The -Pro-Phe-Phe- tripeptide block was identified as a
sequence responsible for this activity [33]. This effect
was also studied by Rossi et al. [34]. In 1991 Siemion
et al. reported that CLA possesses a strong immunosuppressant activity [35]. Details of this finding were presented in a paper by Wieczorek et al. [36]. The influence
J. Pept. Sci. 2006; 12: 569–574
DOI: 10.1002/psc
CYCLOPEPTIDES OF LINUM USITATISSIMUM
of CLA on the humoral response was determined by the
plaque forming cell (PFC) test and the influence on the
cellular immune response by the delayed-type hypersensitivity (DTH) test. It was also found that CLA influences human lymphocyte proliferation in vitro and tempers post adjuvant polyarthritis in rats and haemolytic
anaemia of New Zealand Black mice. The effects of CLA
in these tests were comparable with those exerted by a
known immunosuppressant – cyclosporin A (CsA).
In 1997 Gaymes et al. found that CLA, along with
CsA, inhibits calcium dependent activation of T lymphocytes. However, the CLA concentration required for
complete inhibition was ten times as high as that
of CsA. It was also demonstrated that calcineurin,
a phosphatase involved in T-lymphocyte signalling,
is inhibited by CLA by a mechanism dependent on
cyclophilin A – one of the peptidyl-prolyl cis-trans isomerases. The direct binding of CLA to cyclophilin A was
confirmed by the studies of tryptophane fluorescence
and PPIase assays. This suggests that the molecular
mechanism of CLA action is the same as that of CsA
[37,38]. Gallo et al. who studied the binding of CLA to
cyclophilin A, speculated that the CLA sequence – ValPro-Pro-Phe-Phe- was responsible for this interaction
[39]. Using a hydrophilic CLA analogue: cyclo (-AlaLys-Pro-Phe-Phe-Ala-Lys-Pro-Phe-Phe-) Kemmer et al.
isolated three hepatocellular peptide-binding proteins
from the integral part of plasma membranes and
the cytosol. They were identified as cytochromes
P450IIC13 and P450IIC22, and 3-hydroxy-androgenUDP-glucuronosyltransferase, proteins known for their
ability to bind bile acids [40]. Some years ago, Bell
et al. discovered the antimalarial activity of CLA and
its analogues. It was found that the substitution of
hydrophobic residues by less hydrophobic ones results
in a decrease of the antimalarial activity although such
peptides retained the immunosuppressive properties.
This suggests that the antimalarial activity of CLA does
not depend on its binding with cyclophilin-like receptors. The introduction of D-aromatic residues into the
CLA molecule leads to a decrease in the immunosuppressive activity but has little effect on antimalarial
activity [41].
Analogues
A great number of structural analogues of CLA were
synthesized and examined for their immunosuppressant activity. On the basis of the investigation of rigid
analogues of CLA, Benedetti and Pedone concluded
that the flexibility of the peptide structure plays an
important role in the biological function of this class of
peptides [15]. The results of the Polish group working on
this subject were revised by Siemion et al. The results
obtained for other natural cyclic peptides displaying
structural similarity with CLA, such as antamanide,
cycloamanides, hymenistatin, and hymenamides are
Copyright 2006 European Peptide Society and John Wiley & Sons, Ltd.
571
summarized in that work [42]. It was found that many
of the linear analogues of CLA show immunosuppressive activity and the preservation of the intact Pro–Phe
amide bond is of importance for this biological effect.
The substitution of successive amino acid residues
in the linear peptide Leu-Ile-Ile-Leu-Val-Pro-Phe-Phe
by Gly, with the exception of Gly1 -sequence, leads
to inactive compounds [43]. Shortening of the linear
sequence from the N -terminus results in the decrease
of immunomodulatory effects, but the tetrapeptide ProPro-Phe-Phe was found to be quite potent [44]. Closing
of the sequence by the disulphide bridge between
Mpa (Mpa – mercaptopropionic acid) and Cys residues
situated on the N - and C-terminus of the peptide,
respectively, resulted in an active analogue. The all-D
isomer was also active. The acetylation of the Gly-IleIle-Leu-Val-Pro-Pro-Phe-Phe peptide and its N -terminal
elongation with additional Gly residues evoked a distinct increase in the immunosuppressive potency [45].
The substitution of the successive residues by Ala does
not abolish the biological activity of CLA [46]. In addition, the linear and cyclic analogues of CLA in which
one or both Phe residues were exchanged by Tyr, were
active immunosuppressants, though their activity was
lower than that of the native peptide [47]. The aromatic
region of CLA was also modified by the substitution of
Phe residues by D-Phe, D-Tyr, Trp, and D-Trp residues.
It was found that the change of configuration leads to
a distinct decrease in the immunosuppressive potency
[48]. The CD spectra of these analogues suggest that
this decrease may result from the change of the conformational preferences of these peptides [49,50].
To increase the solubility of CLA, the linear and cyclic
analogues with Thr residue occupying the successive
positions in the -Leu-Ile-Ile- Leu-Val- fragment of the
peptide were synthesized. It was found, however, that
the presence of a single Thr residue does not sufficiently
change the solubility of the resulting peptides. This
substitution does not influence the conformation of
the peptide and preserves its biological activity [51].
Better water-soluble peptides were obtained when one
or two of the Phe residues of CLA were replaced by their
sulphonated derivatives. All linear and cyclic analogues
of this kind were active as immunosuppressors in PFC
and DTH tests [52]. Another approach to increase the
bioavailability of CLA, CLX, and their analogues, was
to link them covalently to the cell-permeable peptides
based on HIV-1 Tat protein sequence [53].
Zabrocki et al. enhanced solubility of linear and
cyclic CLA analogues in water by the substitution of
Leu1 , Leu5 or Val9 residues in the molecule by their
α-hydroxymethyl derivatives. The peptides were four
times soluble in water as the native peptide. However,
in the lymphocyte proliferation assays only peptides
containing α-hydroxymethylleucine (HmL) showed the
inhibitory activity. The most promising, in this respect,
was HmL8 -peptide. It was found that the conformation
J. Pept. Sci. 2006; 12: 569–574
DOI: 10.1002/psc
572
PICUR ET AL.
of this peptide was closest to the conformation
of CLA in the solid state [54]. The same group
synthesized a cyclolinopeptide B analogue with Met
residue substituted by α-hydroxymethylmethionine.
The peptide was non-toxic and inhibited humoral
and cellular immune response (PFC and DTH tests,
respectively) at a degree comparable to cyclosporine A
[55].
To examine if the cis-amide bond in the Pro–Pro
moiety of CLA is important for its inhibitory activity, the
analogues in which two dipeptide segments, Val–Pro
and Pro–Pro, respectively, were replaced by their
tetrazole derivatives, were synthesized by Zabrocki et al
[56]. The tetrazole moiety functions as a cis-amide
bond mimetic in solution, as shown in Figure 2. In
the humoral response test, the cyclic peptides of this
type showed activity that was equal, at the low doses,
to those exerted by CLA and CsA. It was also shown
that the conformation of cyclo-(Leu-Ile-Ile-Leu-Val-Pro(CN)4 -Ala-Phe-Phe) analogue of CLA resembles that
of CLA in the solid state. The same methodology was
applied to antamanide and hymenistatin I analogues
[57,58].
The (2S, 4R)-4-aminopyroglutaminic acid was also
used as a surrogate for a dipeptide moiety with a
fixed cis-amide bond. The CLA analogue resulting
from the cyclization of a structure presented in
Figure 3 inhibited the lymphocyte proliferation much
less efficiently than CsA [59].
To elucidate if the edge-to-face orientation of the two
Phe residues of CLA influences its biological activity,
analogues with one or both Phe residues substituted
by N -benzylglycine were synthesized [60]. It was found
that the edge-to-face orientation as well as the distance
between Phe aromatic rings is important for the
biological activity [61].
Ciα
Ci+1α
Ciα
Ci+1α
N
O
N
H
N
N
N
Figure 2
Tetrazole moiety as a cis-amide bond mimetic.
O
Phe-Phe-OH
NH
H-Leu-Ile-Ile-Leu-Val-HN
O
Figure 3 CLA analogue containing (2S, 4R)-4-aminopyroglutaminic acid.
Copyright 2006 European Peptide Society and John Wiley & Sons, Ltd.
O
COOH
HN
N
Figure 4 The structure of the dipeptide unit containing an
ethylene link bridging two phenylalanine nitrogens [62].
A CLA analogue with the Phe–Phe fragment conformationally constrained by an ethylene linker between
the two nitrogens within the moiety was also synthesized (see Figure 4) [62].
In summary, studies have shown that many modifications of the initial structure of CLA do not abolish
its immunosuppressive potency. However, no analogue
possessing activity higher than CLA was found during these investigations. The results also suggest that
the – Pro-Xxx-Phe- sequence of CLA, where Xxx is
a hydrophobic aliphatic (e.g. Leu, Val), or aromatic
residue, is of importance for the immunosuppressive
activity of CLA analogues.
Acknowledgements
A part of this work was supported by the Ministry of
Scientific Research and Information Technology grant
2P05A04928 (M.C.).
REFERENCES
1. Kaufmann HP, Tobschirbel A. Ueber ein oligopeptid aus leinsamen.
Chem. Ber. 1959; 92: 2805–2809.
2. Prox A, Weygand F. Sequenzanalyse von peptiden durch
kombination von gas chromatographie und massen spectrometrie.
In Peptides Proceedings 8th European Peptide Symposium,
Beyerman HC, van de Linde A, Maasen van den Brink W (eds).
North-Holland: Amsterdam, 1967; 158–172.
3. Weygand F. Entwicklunglinien biochemischer analytik. Z. Anal.
Chem. Freseniu. 1968; 243: 2–17.
4. Obermeier R. Massenspektrometrische Identifizierung substituierter Phenylthiodantoine des Edmanabbaus mit Anwendungen
in der Peptidchemie. PhD Thesis, Munich Technical University,
Munich, 1969.
5. Morita H, Shishido A, Matsumoto T, Takeya K, Itokawa H,
Hirano T, Oka K. Cyclic peptides from higher plants. 42. A
new immunosuppressive cyclic nonapeptide B from Linum
usitatissium. Bioorg. Med. Chem. Lett. 1997; 7: 1269–1272.
6. Morita H, Shishido A, Matsumoto T, Itokawa H, Takeya K. Cyclic
peptides from higher plants. 45. Cyclolinopeptides B–E, new
cyclic peptides from Linum usitatissium. Tetrahedron 1999; 55:
967–976.
7. Matsumoto T, Shishido A, Morita H, Itokawa H, Takeya K.
Cyclolinopeptides F–I, cyclic peptides from linseed. Phytochemistry
2001; 57: 251–260.
8. Picur B, Lisowski M, Siemion IZ. A new cyclolinopeptide containing
nonproteinaceous amino acid N-methyl-4-aminoproline. Lett. Pept.
Sci. 1998; 5: 183–187.
9. Ruchala P, Picur B, Lisowski M, Cierpicki T, Wieczorek Z,
Siemion IZ. Synthesis, conformation, and immunosuppressive
activity of CLX and its analogues. Biopolymers 2003; 70: 497–511.
J. Pept. Sci. 2006; 12: 569–574
DOI: 10.1002/psc
CYCLOPEPTIDES OF LINUM USITATISSIMUM
10. Naider F, Benedetti E, Goodman M. Conformation of cyclolinopeptide A by circular dichroism. Proc. Natl. Acad. Sci. U.S.A. 1971; 68:
1195–1198.
11. Brewster AI, Bovey FA. Conformation of cyclolinopeptide A
observed by nuclear magnetic resonance spectroscopy. Proc. Natl.
Acad. Sci. U.S.A. 1971; 68: 1199–1202.
12. Tonelli AE. Approximate treatment of the conformational
characteristics of a cyclic nonapeptide, cyclolinopeptide A. Proc.
Natl. Acad. Sci. U.S.A. 1971; 68: 1203–1207.
13. Siemion IZ, Klis WA, Sucharda-Sobczyk A, Obermeier R. Conformation of cyclolinopeptide A in solution. Rocz. Chem. 1976; 51:
1489–1498.
14. Di Blasio B, Rossi F, Benedetti E, Pavone V, Pedone C, Temussi PA,
Zanotti G, Tancredi T. Bioactive peptide: solid-state and solution
conformation of cyclolinopeptide A. J. Am. Chem. Soc. 1989; 111:
9089–9098.
15. Benedetti E, Pedone C. Cyclolinopeptide A: inhibitor, immunosuppressor or other? J. Pept. Sci. 2005; 11: 268–272.
16. Tancredi T, Zanotti G, Rossi F, Benedetti E, Pedone C, Temussi PA.
Comparison of the conformations of cyclolinopeptide A in the solid
state and in solution. Biopolymers 1989; 28: 513–523.
17. Neela BS, Manjula MV, Ramakumar S, Balasubramanian D,
Viswamitra MA. Conformation of cyclolinopeptide dihydrate: an
antamanide analogue. Biopolymers 1990; 29: 1499–1501.
18. Raghothama S, Ramakrishnan C, Balasubramanian D, Balaram P.
Conformational analysis of cyclolinopeptide A, a cyclic nonapeptide:
nuclear Overhauser effect and energy minimization studies.
Biopolymers 1989; 28: 573–588.
19. Di Blasio B, Rossi F, Benedetti E, Pavone V, Saviano M, Pedone C,
Zanotti G, Tancredi T. Bioactive peptides: X-ray and NMR
conformational study of [Aib5,6-D-Ala8]cyclolinopeotide A. J. Am.
Chem. Soc. 1992; 114: 8277–8283.
20. Saviano M,
Rossi F,
Filizola M,
Isernia C,
Di
Blasio B,
Benedetti E, Pedone C, Siemion IZ, Pedyczak A. Bioactive peptides:
conformational studies of [Tyr4]cyclolinopeptide A. Biopolymers
1995; 36: 453–460.
21. Castiglione-Morelli MA,
Pastore A,
Pedone C,
Temussi PA,
Zanotti G, Tancredi T. Conformational study of cyclolinopeptide
A. A distance geometry and molecular dynamics approach. Int. J.
Pept. Protein Res. 1991; 37: 81–89.
22. Saviano M, Aida M, Corongiu G. Molecular dynamics simulation
in vacuo and in solution of cyclolinopeptide A: a conformational
study. Biopolymers 1991; 31: 1017–1024.
23. Mazzeo M, Isernia C, Rossi F, Saviano M, Pedone C, Paolillo L,
Benedetti E,
Pavone V.
Conformational
behaviour
of
a
cyclolinopeptide A analogue: two-dimensional NMR study of
cyclo(Pro1-Pro-Phe-Phe-Ac6c-Ile-ala-Val8). J. Pept. Sci. 1995; 1:
330–340.
24. Saviano M, Isernia C, Rossi F, Di Blasio B, Iacovino R, Mazzeo M,
Pedone C, Benedetti E. Solid state structural analysis of the
cyclooctapeptide cyclo-(Pro1- Pro-Phe-Phe-Ac6c-Ile-D-Ala-Val8).
Biopolymers 2000; 53: 189–199.
25. Siemion IZ. A new example of edge-to-face interaction of aromatic
rings in oligopeptides: cyclolinopeptide A. Z. Naturforsch. 1990;
456: 1324–1326.
26. Siemion IZ, Cebrat M, Jankowski A, Lisowski M, Pedyczak A,
Wyslouch A. Does the edge-to-face interaction between aromatic
rings occur in cyclolinopeptide A analogues? Int. J. Pept. Protein
Res. 1994; 44: 61–69.
27. Karle IL, Flippen-Anderson JL, Wieland T. Conformational stability
of antamanide and analogs. Crystal structure of perhydrosymmetric antamanide, cyclic (-Val-Pro-Pro-Cha-Cha-Val-Pro-Pro-ChaCha-). Int. J. Pept. Protein Res. 1989; 33: 422–427.
28. Balasubramanian D, Chopra P, Ardeshir F. Cyclolinopeptide: an
antamanide analog. FEBS Lett. 1976; 65: 69–72.
29. Klis WA, Obermeier R, Siemion IZ, Sucharda-Sobczyk A, Gatner K.
Complexing ability of cyclolinopeptide A. Rocz. Chem. 1977; 51:
1499–1509.
Copyright 2006 European Peptide Society and John Wiley & Sons, Ltd.
573
30. Tancredi T,
Benedetti E,
Grimaldi M,
Pedone C,
Rossi F,
Saviano M, Temussi PA, Zanotti G. Ion binding of cyclolinopeptide
A: an NMR and CD conformational study. Biopolymers 1991; 31:
761–767.
31. Zanotti G, Maione A, Rossi F, Saviano M, Pedone C, Tancredi T.
Bioactive peptides: conformational study of a cystinyl
cycloheptapeptide in its free and calcium complexed forms.
Biopolymers 1993; 33: 1083–1091.
32. Saviano G, Rossi F, Benedetti E, Pedone C, Mierke DF, Maione A,
Zanotti G, Tancredi T, Saviano M. Structural consequences of
metal complexation of cyclo[Pro-Phe-Phe-Ala-Xaa]2 decapeptides.
Chem. – Eur. J. 2001; 7: 1176–1183.
33. Kessler H, Klein M, Müller A, Wagner K, Bats JW, Ziegler K,
Frimmer M. Conformational prerequisites for the in vitro inhibition
of cholate uptake in hepatocytes by cyclic analogues of antamanide
and somatostatin. Angew. Chem., Int. Ed. Engl. 1986; 25: 997–999.
34. Rossi F, Saviano M, Di Talia P, Di Blasio B, Pedone C, Zanotti G,
Mosca M, Saviano G, Tancredi T, Ziegler K, Benedetti E. Solution
and solid state structure of an aib-containing cyclodecapeptide
inhibiting the cholate uptake in hepatocytes. Biopolymers 1996;
40: 465–478.
35. Siemion IZ, Bengtsson B, Trojnar J, Wieczorek Z. New peptide
immunosuppressors. In Peptides 1990 Proceedings 21st European
Peptide Symposium, Giralt E, Andreu D (eds). ESCOM: Leiden,
1991; 882–884.
36. Wieczorek Z, Bengtsson B, Trojnar J, Siemion IZ. Immunosuppressive activity of cyclolinopeptide A. Pept. Res. 1991; 4: 275–283.
37. Gaymes TJ, Cebrat M, Siemion IZ, Kay JE. Cyclolinopeptide
A (CLA) mediates its immunosuppressive activity through
cyclophilin-dependent calcineurin inactivation. FEBS Lett. 1997;
418: 224–227.
38. Gaymes TJ, Carrett NJ, Patel N, Kay JE, Siemion IZ. Effects of
cyclolinopeptide A on T lymphocyte activation and peptidyl prolyl
isomerase activity. Biochem. Soc. Trans. 1996; 24: 90S.
39. Gallo P, Saviano M, Rossi F, Pavone V, Pedone C, Ragone R,
Stiuso P, Colonna G. Specific interaction between cyclophilin and
cyclic peptides. Biopolymers 1995; 36: 273–281.
40. Kemmer H, Tripier D, Jouvenal K, Scriba D, Zanotti G, Maione AM,
Ziegler K. Binding proteins for cyclic and linear oligopeptides in
plasma membranes and the cytosol of rat hepatocytes. Biochem.
Pharmacol. 1997; 54: 481–490.
41. Bell A, McSteen PM, Cebrat M, Picur B, Siemion IZ. Antimalarial
activity of cyclolinopeptide A and its analogues. Acta Pol. Pharm.
2000; 57(Suppl.): 134–136.
42. Siemion IZ, Cebrat M, Wieczorek Z. Cyclolinopeptides and their
analogs – a new family of peptide immunosuppressants affecting
the calcineurin system. Arch. Immunol. Ther. Exp. 1999; 47:
143–153.
43. Siemion IZ, Bengtsson B, Trojnar J, Pedyczak A, Cebrat M,
Zimecki M, Wieczorek Z. Immunosuppressive activity of cyclolinopeptide A analogs. In Peptides Chemistry and Biology,
Proceedings 12th American Peptide Symposium, Smith JA, Rivier JE
(eds). ESCOM: Leiden, 1992; 871–872.
44. Siemion IZ, Pedyczak A, Strug I, Wieczorek Z. Synthesis and
biological studies on analogs of cyclolinopeptide A with a shortened
peptide chain. Arch. Immunol. Ther. Exp. 1994; 42: 459–465.
45. Siemion IZ, Cebrat M, Pedyczak A, Zimecki M, Wieczorek Z.
Synthesis and immunosuppressive activity of glycine containing
linear analogs of cyclolinopeptide A. Arch. Immunol. Ther. Exp.
1993; 41: 285–289.
46. Wieczorek Z, Zimecki M, Pedyczak A, Lisowski M, Siemion IZ.
Immunosuppressive activity of alanine analogs of cyclolinopeptide
A. Arch. Immunol. Ther. Exp. 1993; 41: 291–296.
47. Wieczorek Z, Pedyczak A, Bodalski T, Lisowski M, Trojnar J,
Zimecki M, Siemion IZ. Immunosuppressive activity of tyrosine
analogues of cyclolinopeptide A. Arch. Immunol. Ther. Exp. 1992;
40: 213–216.
J. Pept. Sci. 2006; 12: 569–574
DOI: 10.1002/psc
574
PICUR ET AL.
48. Cebrat M, Lisowski M, Siemion IZ, Wieczorek Z. The cyclolinopeptide A analogues with D-Phe, D-Tyr, and L- and D-Trp residues.
Pol. J. Chem. 1997; 71: 1401–1412.
49. Siemion IZ, Lisowski M, Cebrat M, Pedyczak A, Wyslouch A.
Chirooptical properties of aromatic residues in cyclolinopeptide
A and its analogues. Pol. J. Chem. 1994; 68: 963–968.
50. Siemion IZ, Cebrat M, Lisowski M. Further investigations on
the optical activity of aromatic residues in cyclolinopeptide A
analogues. Pol. J. Chem. 2000; 74: 955–964.
51. Siemion IZ, Cebrat M, Lisowski M, Zimecki M, Wieczorek Z.
Immunosuppressive activity of threonine-containing analogues of
cyclolinopeptide A. Arch. Immunol. Ther. Exp. 1992; 40: 257–261.
52. Cebrat M, Lisowski M, Siemion IZ, Zimecki M, Wieczorek Z.
Sulfonated
analogues
of
cyclolinopeptide
A:
synthesis,
immunosuppressive activity and CD studies. J. Pept. Res. 1997;
49: 415–420.
53. Cebrat M, Ruchala P, Micewicz E, Woznica I, Picur B, Szewczuk Z.
Analogues of cyclolinopeptides conjugated to the cell-permeable
sequences. In 18th Polish Peptide Symposium, Wroc3aw, 4–8
September 2005; 98–99.
54. Zubrzak P, Banas A, Kaczmarek K, Leplawy MT, Sochacki M,
Kowalski ML, Szkudlinska B, Zabrocki J, Di Lello P, Isernia C,
Saviano M, Pedone C, Benedetti E. Analogues of cyclolinopeptide A
containing alpha-hydroxymethyl amino acid residues. Biopolymers
2005; 80: 347–356.
55. Witkowska R, Donigiewicz A, Zimecki M, Zabrocki J. New analogue
of cyclolinopeptide B modified by amphiphilic residue of alphahydroxymethylmethionine. Acta Biochim. Pol. 2004; 51: 67–72.
56. Kaczmarek K, Jankowski S, Siemion IZ, Wieczorek Z, Benedetti E,
Di Lello P, Isernia C, Saviano M, Zabrocki J. Tetrazole analogues
Copyright 2006 European Peptide Society and John Wiley & Sons, Ltd.
57.
58.
59.
60.
61.
62.
of cyclolinopeptide A: synthesis, conformation, and biology.
Biopolymers 2002; 63: 343–357.
Zubrzak P, Kociolek K, Smoluch M, Silberring J, Kowalski ML,
Szkudlinska B, Zabrocki J. Search for new synthetic immunosuppressants II. Tetrazole analogues of hymenistatin I. Acta Biochim.
Pol. 2001; 48: 1151–1154.
Zubrzak P, Kaczmarek K, Kowalski ML, Szkudlin’ska B, Zabrocki J.
Search for new synthetic immunosuppressants. Antamanide
analogues containing the tetrazole ring as a cis-peptide bond
mimetic. Pol. J. Chem. 2001; 75: 1869–1876.
Kaczmarek K, Silberring J, Smoluch M, Kowalski ML,
Grochulska E, Szkudlin’ska B, Zabrocki J. Cyclolinopeptide A
analogue containing (2S,4R)-4-aminopyroglutamic acid (4tAPy)
residue as a cis-peptide bond motif. In Peptides 2000 Proceedings
26th European Peptide Symposium, Martinez J, Fehrene JA (eds).
EDK: Paris, 2001; 821–822.
Leplawy MT, Zubrzak P, Olejniczak B, Paneth P, Smoluch M,
Silberring J,
Kowalski ML,
Szkudlin’ska B,
Grochulska E,
Zabrocki J. Cyclolinopeptide A analogues containing Nbenzoylglycine as a peptoid building block. In Peptides 2000
Proceedings 26th European Peptide Symposium, Martinez J,
Fehrene JA (eds). EDK: Paris, 2001; 859–860.
Zubrzak P, Leplawy MT, Kowalski ML, Szkudlin’ska B, Paneth P,
Silberring J, Suder P, Zabrocki J. Correlating biological activity
with calculated geometric motifs in cyclolinopeptide A analogs.
J. Phys. Org. Chem. 2004; 17: 625–630.
Katarzynska J, Bilska M, Adamek E, Zimecki M, Zabrocki J.
Analogues of cyclolinopeptide A containing conformationally
constrained dipeptide fragments. In 18th Polish Peptide
Symposium, Wroc3aw, 4–8 September 2005; 130–131.
J. Pept. Sci. 2006; 12: 569–574
DOI: 10.1002/psc